CD34+细胞动员、自体移植物细胞组成和套细胞淋巴瘤患者的预后。

IF 16.4 1区 化学 Q1 CHEMISTRY, MULTIDISCIPLINARY
Accounts of Chemical Research Pub Date : 2023-08-23 eCollection Date: 2023-10-01 DOI:10.1159/000531799
Antti Samuli Turunen, Outi Kuittinen, Hanne Kuitunen, Kaija Vasala, Karri Penttilä, Minna Harmanen, Leena Keskinen, Pentti Mäntymaa, Jukka Pelkonen, Ville Varmavuo, Esa Jantunen, Anu Partanen
{"title":"CD34+细胞动员、自体移植物细胞组成和套细胞淋巴瘤患者的预后。","authors":"Antti Samuli Turunen,&nbsp;Outi Kuittinen,&nbsp;Hanne Kuitunen,&nbsp;Kaija Vasala,&nbsp;Karri Penttilä,&nbsp;Minna Harmanen,&nbsp;Leena Keskinen,&nbsp;Pentti Mäntymaa,&nbsp;Jukka Pelkonen,&nbsp;Ville Varmavuo,&nbsp;Esa Jantunen,&nbsp;Anu Partanen","doi":"10.1159/000531799","DOIUrl":null,"url":null,"abstract":"<p><strong>Backgound: </strong>Autologous stem cell transplantation (ASCT) is a standard treatment in transplant-eligible mantle cell lymphoma (MCL) patients after first-line chemoimmunotherapy.</p><p><strong>Study design and methods: </strong>This prospective multicenter study evaluated the impact of CD34<sup>+</sup> cell mobilization and graft cellular composition analyzed by flow cytometry on hematologic recovery and outcome in 42 MCL patients.</p><p><strong>Results: </strong>During CD34<sup>+</sup> cell mobilization, a higher blood CD34<sup>+</sup> cell count (>30 × 10<sup>6</sup>/L) was associated with improved overall survival (median not reached [NR] vs. 57 months, <i>p</i> = 0.04). The use of plerixafor did not impact outcome. Higher number of viable cryopreserved graft CD34<sup>+</sup> cells (>3.0 × 10<sup>6</sup>/kg) was associated with faster platelet (median 11 vs. 15 days, <i>p</i> = 0.03) and neutrophil (median 9 vs. 10 days, <i>p</i> = 0.02) recovery posttransplant. Very low graft CD3<sup>+</sup>CD8<sup>+</sup> cell count (≤10 × 10<sup>6</sup>/kg) correlated with worse progression-free survival (PFS) (HR 4.136, 95% CI 1.547-11.059, <i>p</i> = 0.005). On the other hand, higher absolute lymphocyte count >2.5 × 10<sup>9</sup>/L at 30 days after ASCT (ALC-30) was linked with better PFS (median NR vs. 99 months, <i>p</i> = 0.045) and overall survival (median NR in either group, <i>p</i> = 0.05).</p><p><strong>Conclusions: </strong>Better mobilization capacity and higher graft CD3<sup>+</sup>CD8<sup>+</sup> cell count had a positive prognostic impact in this study, in addition to earlier lymphocyte recovery (ALC-30>2.5 × 10<sup>6</sup>/L). These results need to be validated in another study with a larger patient cohort.</p>","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2023-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601603/pdf/","citationCount":"1","resultStr":"{\"title\":\"CD34<sup>+</sup> Cell Mobilization, Autograft Cellular Composition and Outcome in Mantle Cell Lymphoma Patients.\",\"authors\":\"Antti Samuli Turunen,&nbsp;Outi Kuittinen,&nbsp;Hanne Kuitunen,&nbsp;Kaija Vasala,&nbsp;Karri Penttilä,&nbsp;Minna Harmanen,&nbsp;Leena Keskinen,&nbsp;Pentti Mäntymaa,&nbsp;Jukka Pelkonen,&nbsp;Ville Varmavuo,&nbsp;Esa Jantunen,&nbsp;Anu Partanen\",\"doi\":\"10.1159/000531799\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Backgound: </strong>Autologous stem cell transplantation (ASCT) is a standard treatment in transplant-eligible mantle cell lymphoma (MCL) patients after first-line chemoimmunotherapy.</p><p><strong>Study design and methods: </strong>This prospective multicenter study evaluated the impact of CD34<sup>+</sup> cell mobilization and graft cellular composition analyzed by flow cytometry on hematologic recovery and outcome in 42 MCL patients.</p><p><strong>Results: </strong>During CD34<sup>+</sup> cell mobilization, a higher blood CD34<sup>+</sup> cell count (>30 × 10<sup>6</sup>/L) was associated with improved overall survival (median not reached [NR] vs. 57 months, <i>p</i> = 0.04). The use of plerixafor did not impact outcome. Higher number of viable cryopreserved graft CD34<sup>+</sup> cells (>3.0 × 10<sup>6</sup>/kg) was associated with faster platelet (median 11 vs. 15 days, <i>p</i> = 0.03) and neutrophil (median 9 vs. 10 days, <i>p</i> = 0.02) recovery posttransplant. Very low graft CD3<sup>+</sup>CD8<sup>+</sup> cell count (≤10 × 10<sup>6</sup>/kg) correlated with worse progression-free survival (PFS) (HR 4.136, 95% CI 1.547-11.059, <i>p</i> = 0.005). On the other hand, higher absolute lymphocyte count >2.5 × 10<sup>9</sup>/L at 30 days after ASCT (ALC-30) was linked with better PFS (median NR vs. 99 months, <i>p</i> = 0.045) and overall survival (median NR in either group, <i>p</i> = 0.05).</p><p><strong>Conclusions: </strong>Better mobilization capacity and higher graft CD3<sup>+</sup>CD8<sup>+</sup> cell count had a positive prognostic impact in this study, in addition to earlier lymphocyte recovery (ALC-30>2.5 × 10<sup>6</sup>/L). These results need to be validated in another study with a larger patient cohort.</p>\",\"PeriodicalId\":1,\"journal\":{\"name\":\"Accounts of Chemical Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":16.4000,\"publicationDate\":\"2023-08-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601603/pdf/\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Accounts of Chemical Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000531799\",\"RegionNum\":1,\"RegionCategory\":\"化学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/10/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MULTIDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000531799","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 1

摘要

背景:自体干细胞移植(ASCT)是一线化学免疫治疗后符合移植条件的套细胞淋巴瘤(MCL)患者的标准治疗方法。研究设计和方法:这项前瞻性多中心研究评估了流式细胞术分析的CD34+细胞动员和移植物细胞组成对42名MCL患者血液学恢复和预后的影响。结果:在CD34+细胞动员过程中,较高的血液CD34+细胞计数(>30×106/L)与总生存率的提高有关(中位未达到[NR],而57个月,p=0.04)。使用普利沙福不会影响结果。更高数量的活的冷冻保存移植物CD34+细胞(>3.0×106/kg)与移植后更快的血小板(中位数11天与15天,p=0.03)和中性粒细胞(中位数9天与10天,p=0.02)恢复有关。极低的移植物CD3+CD8+细胞计数(≤10×106/kg)与较差的无进展生存期(PFS)相关(HR 4.136,95%CI 1.547-11.059,p=0.005),ASCT(ALC-30)后30天,较高的绝对淋巴细胞计数>2.5×109/L与较好的PFS(中位NR vs.99个月,p=0.045)和总生存率(两组中位NR,p=0.05)有关。这些结果需要在另一项具有更大患者队列的研究中得到验证。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

CD34<sup>+</sup> Cell Mobilization, Autograft Cellular Composition and Outcome in Mantle Cell Lymphoma Patients.

CD34<sup>+</sup> Cell Mobilization, Autograft Cellular Composition and Outcome in Mantle Cell Lymphoma Patients.

CD34<sup>+</sup> Cell Mobilization, Autograft Cellular Composition and Outcome in Mantle Cell Lymphoma Patients.

CD34+ Cell Mobilization, Autograft Cellular Composition and Outcome in Mantle Cell Lymphoma Patients.

Backgound: Autologous stem cell transplantation (ASCT) is a standard treatment in transplant-eligible mantle cell lymphoma (MCL) patients after first-line chemoimmunotherapy.

Study design and methods: This prospective multicenter study evaluated the impact of CD34+ cell mobilization and graft cellular composition analyzed by flow cytometry on hematologic recovery and outcome in 42 MCL patients.

Results: During CD34+ cell mobilization, a higher blood CD34+ cell count (>30 × 106/L) was associated with improved overall survival (median not reached [NR] vs. 57 months, p = 0.04). The use of plerixafor did not impact outcome. Higher number of viable cryopreserved graft CD34+ cells (>3.0 × 106/kg) was associated with faster platelet (median 11 vs. 15 days, p = 0.03) and neutrophil (median 9 vs. 10 days, p = 0.02) recovery posttransplant. Very low graft CD3+CD8+ cell count (≤10 × 106/kg) correlated with worse progression-free survival (PFS) (HR 4.136, 95% CI 1.547-11.059, p = 0.005). On the other hand, higher absolute lymphocyte count >2.5 × 109/L at 30 days after ASCT (ALC-30) was linked with better PFS (median NR vs. 99 months, p = 0.045) and overall survival (median NR in either group, p = 0.05).

Conclusions: Better mobilization capacity and higher graft CD3+CD8+ cell count had a positive prognostic impact in this study, in addition to earlier lymphocyte recovery (ALC-30>2.5 × 106/L). These results need to be validated in another study with a larger patient cohort.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Accounts of Chemical Research
Accounts of Chemical Research 化学-化学综合
CiteScore
31.40
自引率
1.10%
发文量
312
审稿时长
2 months
期刊介绍: Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance. Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信